https://oncodaily.com Oncology News, Cancer Research & Clinical Insights Wed, 04 Nov 2026 18:20:21 +0000 en-US 10 Oncodaily.com https://oncodaily.com/pub/themes/oncodailynews/img/logo-ODN-round.png https://oncodaily.com https://oncodaily.com/pub/uploads/2025/10/OD-favicon-blank-320x320.webp https://oncodaily.com 32 32 https://oncodaily.com/oncolibrary/immune-oncology/immuno-oncology-november Wed, 04 Nov 2026 18:19:49 +0000 eba70c34100bacc96909bbb2b79234c3

The first week of November brings together updates across immuno-oncology, with posts covering personalized cancer vaccines, AI-assisted toxicity detection, organ preservation, lung cancer treatment, and emerging mechanisms of antitumor immunity. […]]]> https://oncodaily.com/oncolibrary/lung-oncology/ivonescimab-perioperative Wed, 04 Nov 2026 18:18:29 +0000 0611d6ed9347db9523860028078eb347

A phase II study published in Nature Medicine reports encouraging pathological responses with perioperative ivonescimab, a bispecific antibody targeting PD-1 and VEGF, in patients with resectable stage II–IIIB non-small cell […]]]> https://oncodaily.com/industry/peel-therapeutics-624894 Wed, 04 Nov 2026 18:18:27 +0000 e435ee54e7718e7ad8a2723a9b0cff4d

Peel Therapeutics shared on LinkedIn: “We are proud to share that Peel Therapeutics was selected as one of five finalists for the Inaugural Prix Galien Patient First Award in Honor […]]]> https://oncodaily.com/science/neil-stone-head-and-neck-cancer-624916 Wed, 04 Nov 2026 18:17:40 +0000 b663a1ad1c985468b98d0a8756b5a7bb

Neil Stone, Honorary Associate Professor at University College London, shared on X: “A real cancer breakthrough this week: petosemtamab plus pembrolizumab halved the risk of death in a phase 3 […]]]> https://oncodaily.com/community/cholangiocarcinoma-624908 Wed, 04 Nov 2026 18:14:49 +0000 a96a582f4427237090913c7b1136baf5

Cholangiocarcinoma Foundation (CCF) shared on X: “On this season’s finale of Food Network’s Halloween Baking Championship, baker Kyle Caulkins dedicated his final cake to the people who mean the most […]]]> https://oncodaily.com/genitourinary-oncology/cystectomy-mibc Wed, 04 Nov 2026 17:57:20 +0000 cc10a7d9bbfc2a242a6b1fc4d3b76ed8

The management of muscle-invasive bladder cancer (MIBC) is evolving with the introduction of more effective neoadjuvant and perioperative systemic therapies. As treatment responses improve, an increasing number of patients are […]]]> Muscle-Invasive Bladder Cancer: Outcomes of Patients Who Declined Radical Cystectomy - OncoDaily nonadult https://oncodaily.com/gastrointestinal-oncology/biliary-tract-cancer-2 Wed, 04 Nov 2026 16:57:33 +0000 e2dd0217ae76a4b976708ca6a44802c3

The addition of immune checkpoint inhibitors to gemcitabine–cisplatin chemotherapy has established a new first-line standard for advanced biliary tract cancer (BTC). However, disease progression remains common, and subsequent treatment options […]]]> Advanced Biliary Tract Cancer: Real-World Outcomes of First-Line Chemoimmunotherapy and Subsequent Targeted Therapy - OncoDaily nonadult https://oncodaily.com/not-to-miss/zanubrutinib-beone-625031 Wed, 04 Nov 2026 16:42:47 +0000 cec812f8a016988ec5dd69d2513c13ee

A chemotherapy-free treatment for newly diagnosed mantle cell lymphoma has moved closer to potential FDA approval after a Phase 3 trial demonstrated a 43% reduction in the risk of disease […]]]> https://oncodaily.com/technology/merck624237 Wed, 04 Nov 2026 16:40:05 +0000 8c448518a5f5c4552a65c8923b4a102e

Merck KGaA, Darmstadt, Germany, has agreed to sell its contract development and manufacturing organization (CDMO) business to Lonza. The Swiss CDMO will pay a mid-triple-digit million-euro amount, and the deal […]]]> https://oncodaily.com/dialogues/expert-discussion-624934 Wed, 04 Nov 2026 16:20:49 +0000 3cdba12987f022586909e972f6c8dc89

At the Community Oncology Global Congress (COGC 2026), organized by OncoDaily, Suman S. Karanth, Additional Director of Medical Oncology at Fortis Memorial Research Institute in Gurugram, moderated an expert discussion […]]]> Expert Discussion at COGC 2026: The Right First Investments in Precision Oncology - OncoDaily nonadult